Developing Novel TRH-based Drug Treatment for Neurodegenerative Diseases
Neuropath Therapeutics, located in Dublin, Ireland, is a late preclinical stage biotech developing an innovative neurotherapeutic drug treatment based on thyrotropin-releasing hormone (TRH) – a naturally occurring neuropeptide, long recognized for its broad range of neurotherapeutic actions.
Our mission is to deliver first-in-class TRH-based therapeutics to mitigate cognitive and motor impairment and slow disease progression in patients with neurodegenerative diseases (NDs) and other conditions of compromised brain health.
Founded on discoveries at Trinity College Dublin (TCD), Neuropath’s new generation TRH-based compounds incorporate a novel design that overcomes pharmacological limitations that historically have limited clinical exploitation of TRH.
This distinct neurotherapeutic strategy counters multiple pathogenic processes central to the etiology of NDs - i.e., it provides a multifactorial therapeutic approach. As such, TRH-based neurotherapeutics hold major clinical and commercial potential across a range of indications, such as Alzheimer’s Disease, ALS/MND, and traumatic brain injury, among others.
Neuropath’s lead candidate has successfully completed comprehensive preclinical development with top-tier CROs, including an IND/CTA-enabling workup. This orphan-designated lead (granted for ALS by FDA and EMA) is positioned for first-in-human/Phase 1 clinical studies and early proof of principle.
